Merck announces TroFuse-005 trial evaluating sacituzumab tirumotecan met primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer

Published: 2026-05-18 06:50:21 ET MRK

Published on 05/18/2026 at 06:50 am EDT